TherapeuticsMD Inc - Asset Resilience Ratio
TherapeuticsMD Inc (TXMD) has an Asset Resilience Ratio of 0.13% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check how strategically is TherapeuticsMD Inc's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2017)
This chart shows how TherapeuticsMD Inc's Asset Resilience Ratio has changed over time. See TherapeuticsMD Inc (TXMD) net asset quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down TherapeuticsMD Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see TherapeuticsMD Inc (TXMD) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $68.41K | 0.13% |
| Total Liquid Assets | $68.41K | 0.13% |
Asset Resilience Insights
- Limited Liquidity: TherapeuticsMD Inc maintains only 0.13% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
TherapeuticsMD Inc Industry Peers by Asset Resilience Ratio
Compare TherapeuticsMD Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Huadong Medicine Co Ltd
SHE:000963 |
Drug Manufacturers - Specialty & Generic | 0.05% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436 |
Drug Manufacturers - Specialty & Generic | -2.56% |
|
Celltrion Pharm Inc
KQ:068760 |
Drug Manufacturers - Specialty & Generic | 12.49% |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799 |
Drug Manufacturers - Specialty & Generic | 0.40% |
Annual Asset Resilience Ratio for TherapeuticsMD Inc (2011–2017)
The table below shows the annual Asset Resilience Ratio data for TherapeuticsMD Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2017-12-31 | 0.00% | $0.00 | $143.23 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $142.47 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $73.73 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $59.08 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $62.02 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $5.82 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $1.44 Million | -- |
About TherapeuticsMD Inc
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States and internationally. Its products portfolio includes IMVEXXY for the treatment of moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause; BIJUVA to treat moderate-to-severe vasomotor symptoms due to menopause in women with a uterus; and ANNOVERA, a ring-shaped contraceptive vag… Read more